Is ERAS Worth Buying in 2026?

Erasca, Inc. Common Stock

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-04-19

Here’s whether Erasca, Inc. Common Stock (ERAS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+10.71% over 10 days); strong 1-year return of +1524.8%; 3-month momentum positive (+97.6%). Concerns: RSI 75 — overbought, elevated pullback risk. Currently 3.9% off its 52-week high. Score: +5/7.

Ready to act on this? 📈 Trade on Webull

ERAS is in a confirmed uptrend, trading above both its 50-day ($14.74) and 200-day ($6.05) moving averages. With an RSI of 75.4, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +1524.8% compares to +35.1% for SPY (beat the market by 1489.7%).

$10,000 invested 1 year ago → $162,479 today
vs. S&P 500 (SPY) — same period beat market by 1489.7%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($6.05)
Above 50-day MA ($14.74)
!RSI(14) neutral zone (30–70) — currently 75.4
Positive return (+1524.8%)
Within 10% of period high (−3.9%)
Period Range $19.01
$1.06 $19.78
RSI (14) 75.4
0 · OversoldOverbought · 100

Key Metrics

Price$19.01
Period Return+1524.8%
Period High$19.78
Period Low$1.06
Drawdown−3.9%
MA-50$14.74
MA-200$6.05
RSI (14)75.4
Avg Volume (30d)5.7M
vs. SPYbeat by 1489.7%
Return Rank#11 of 996

Trade ERAS

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers